Business Description
Changzhou Qianhong Biopharma Co Ltd
NAICS : 325412
SIC : 2834
ISIN : CNE100001070
Share Class Description:
SZSE:002550: Class ACompare
Compare
Traded in other countries / regions
002550.China IPO Date
2011-02-18Description
Changzhou Qianhong Biopharma Co Ltd engages in the research and development, production, and sale of biopharmaceutical products with the focus on polysaccharides and enzymes in China. The company provides various products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; and kallidinogenase kallikrein and heparinoid.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.11 | |||||
| Equity-to-Asset | 0.89 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | 0.25 | |||||
| Interest Coverage | 36.93 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 16.3 | |||||
| Beneish M-Score | -3.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.2 | |||||
| 3-Year EPS without NRI Growth Rate | -5.4 | |||||
| 3-Year FCF Growth Rate | 16.2 | |||||
| 3-Year Book Growth Rate | 5.7 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.81 | |||||
| 9-Day RSI | 49.39 | |||||
| 14-Day RSI | 48.81 | |||||
| 6-1 Month Momentum % | -4.56 | |||||
| 12-1 Month Momentum % | 3.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.58 | |||||
| Quick Ratio | 5.19 | |||||
| Cash Ratio | 3.54 | |||||
| Days Inventory | 270.88 | |||||
| Days Sales Outstanding | 71.99 | |||||
| Days Payable | 19.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.2 | |||||
| Dividend Payout Ratio | 0.8 | |||||
| 3-Year Dividend Growth Rate | -21.7 | |||||
| Forward Dividend Yield % | 2.2 | |||||
| 5-Year Yield-on-Cost % | 2.65 | |||||
| Shareholder Yield % | 3.24 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 47.46 | |||||
| Operating Margin % | 11.08 | |||||
| Net Margin % | 12 | |||||
| FCF Margin % | 38.27 | |||||
| ROE % | 8.16 | |||||
| ROA % | 7.03 | |||||
| ROIC % | 7.72 | |||||
| ROC (Joel Greenblatt) % | 15.49 | |||||
| ROCE % | 8.77 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 34.68 | |||||
| PE Ratio without NRI | 36.07 | |||||
| Shiller PE Ratio | 31.82 | |||||
| Price-to-Owner-Earnings | 55.77 | |||||
| PS Ratio | 4.18 | |||||
| PB Ratio | 2.86 | |||||
| Price-to-Tangible-Book | 3.13 | |||||
| Price-to-Free-Cash-Flow | 10.86 | |||||
| Price-to-Operating-Cash-Flow | 9.52 | |||||
| EV-to-EBIT | 28.05 | |||||
| EV-to-EBITDA | 28.05 | |||||
| EV-to-Revenue | 3.75 | |||||
| EV-to-FCF | 9.99 | |||||
| Price-to-Projected-FCF | 2.19 | |||||
| Price-to-Median-PS-Value | 0.96 | |||||
| Price-to-Graham-Number | 2.24 | |||||
| Price-to-Net-Current-Asset-Value | 5.46 | |||||
| Price-to-Net-Cash | 16.39 | |||||
| Earnings Yield (Greenblatt) % | 3.57 | |||||
| FCF Yield % | 9.22 | |||||
| Forward Rate of Return (Yacktman) % | -10.55 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Changzhou Qianhong Biopharma Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,667.151 | ||
| EPS (TTM) (Â¥) | 0.156 | ||
| Beta | 0.21 | ||
| Volatility % | 24.61 | ||
| 14-Day RSI | 48.81 | ||
| 14-Day ATR (Â¥) | 0.198444 | ||
| 20-Day SMA (Â¥) | 5.437 | ||
| 12-1 Month Momentum % | 3.82 | ||
| 52-Week Range (Â¥) | 4.2 - 6.34 | ||
| Shares Outstanding (Mil) | 1,279.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Changzhou Qianhong Biopharma Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Changzhou Qianhong Biopharma Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Changzhou Qianhong Biopharma Co Ltd Frequently Asked Questions
What is Changzhou Qianhong Biopharma Co Ltd(SZSE:002550)'s stock price today?
The current price of SZSE:002550 is ¥5.41. The 52 week high of SZSE:002550 is ¥6.34 and 52 week low is ¥4.20.
When is next earnings date of Changzhou Qianhong Biopharma Co Ltd(SZSE:002550)?
The next earnings date of Changzhou Qianhong Biopharma Co Ltd(SZSE:002550) is .
Does Changzhou Qianhong Biopharma Co Ltd(SZSE:002550) pay dividends? If so, how much?
The Dividend Yield %  of Changzhou Qianhong Biopharma Co Ltd(SZSE:002550) is 2.2% (As of Today), Highest Dividend Payout Ratio of Changzhou Qianhong Biopharma Co Ltd(SZSE:002550) was 1.92. The lowest was 0.47. And the median was 0.99. The  Forward Dividend Yield % of Changzhou Qianhong Biopharma Co Ltd(SZSE:002550) is 2.2%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers